8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT


                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                Date of Report (Date of earliest event reported)

                                 MARCH 11, 2004


                                  XTRANA, INC.
             (Exact name of registrant as specified in its charter)

          DELAWARE                  001-14257                    58-1729436
(State or other jurisdiction       (Commission                 (IRS Employer
       of incorporation)           File Number)              Identification No.)


       590 BURBANK STREET, SUITE 205, BROOMFIELD, COLORADO         80020
            (Address of principal executive offices)             (Zip Code)


       Registrant's telephone number, including area code: (303) 466-4424





ITEM 5. - OTHER EVENTS AND REGULATION FD DISCLOSURE

         On March 11, 2004, Xtrana,  Inc. (the "Company") issued a press release
announcing the  appointment of James H.  Chamberlain as Interim Chief  Executive
Officer, replacing Timothy J. Dahltorp, its current Chief Executive Officer, who
will be leaving  the Company  effective  March 19,  2004.  The  Company's  press
release further  announced that John C. Gerdes,  Ph.D.,  has been appointed as a
director.  A copy of the press  release is  attached to this Form 8-K as Exhibit
99.1 and is incorporated herein by reference.


ITEM 7. - FINANCIAL STATEMENTS AND EXHIBITS

         (a)      Financial Statements.

                  None.

         (b)      Pro Forma Financial Information.

                  None.

         (c)      Exhibits.

                  99.1     Press release dated March 11, 2004


                                       2



                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


March 12, 2004                               XTRANA, INC.


                                             /S/ TIMOTHY J. DAHLTORP
                                             -------------------------------
                                             Timothy J. Dahltorp,
                                             Chief Executive Officer


                                       3



                                  EXHIBIT INDEX


EXHIBIT NUMBER          DESCRIPTION

    99.1                Press release dated March 11, 2004


                                       4

EX-99

                                                                    EXHIBIT 99.1

PRESS RELEASE

    XTRANA ANNOUNCES THE APPOINTMENT OF JAMES H. CHAMBERLAIN AS INTERIM CEO,
                         AND JOHN C. GERDES AS DIRECTOR

BROOMFIELD,  Colo.--March 11,  2004--Xtrana,  Inc. (OTCBB: XTRN) announced today
that James H. Chamberlain, a current Director of the Company, has been appointed
Interim Chief Executive Officer,  replacing Timothy J. Dahltorp,  who is leaving
the Company effective March 19, 2004.  Additionally,  John C. Gerdes,  Ph.D. has
joined the Company's Board of Directors.

Michael  Bick,  Chairman of the Board,  stated:  "We are grateful to Tim for his
leadership  of Xtrana and wish him well in his future  endeavors.  Jim brings to
the Company extensive experience,  and his primary focus will be to finalize the
closure  of  the  sale  of  Xtrana's  intellectual  property  and  to  lead  the
identification  process of reverse  merger  prospects  for the  Company.  We are
fortunate to have Jim take on this role for the  Company."  Mr. Bick  continued:
"John Gerdes  previously  resigned  from the Board while  considering a possible
transaction  as a principal  relating to the sale of the  Company's  technology.
Since  that  transaction  is  no  longer  contemplated,  the  Board  desired  to
re-appoint John to the Board in order to more effectively  represent the current
ownership of the Company,  and to bring back John's  valuable  experience to the
Board. We are very excited to have John join the Board."

James H.  Chamberlain was the founder of Biosource  International,  Inc. (Nasdaq
NMS: BIOI), a California-based  company dedicated to the research,  development,
manufacturing,  and  marketing  of  biomedical  products to the  diagnostic  and
research  markets.  Mr.  Chamberlain  also  serves as  Chairman  of the Board of
Directors  of  Marlingen  BioSciences,   Inc.,  a  Maryland-based  biotechnology
company,  and is the President of JHC Consulting,  Inc., a private life sciences
and management consulting firm. Prior to founding Biosource, Mr. Chamberlain was
the Manager of Business  Development for Amgen, Inc. Mr. Chamberlain  received a
B.S.  degree in biology and chemistry from West Virginia  University in 1969 and
attended the MBA  Executive  Program at  Pepperdine  University  from 1978 until
1980.

Dr.  Gerdes is the Vice  President  of Research and  Development  for Xtrana and
became a director and Chief  Scientific  Officer  concurrent  with the Company's
merger with Xtrana in 2000. In 2003, Dr. Gerdes resigned as a director of Xtrana
due,  in part,  to his  desire  to  submit  an  offer  for the  purchase  of our
intellectual  property. In 1996, he conceived of a unique point of care approach
for DNA  diagnostics,  the  development  of which  resulted in the  formation of
Xtrana.  From  1988 to 1998,  he was the  Director  of  Paternity  Analysis  and
Clinical Director at IAD where he supervised clinical testing and introduced PCR
and other nucleic acid based  clinical  tests.  He has  twenty-one  publications
primarily focused on molecular methods of virus detection. He has recently filed
four patents that provide the technical  foundation of the Xtrana business plan.
Dr. Gerdes  received a B.S. in  Microbiology  from the  University of Wyoming in
1970, and a Ph.D. in Microbial Genetics from the University of California at Los
Angeles (UCLA) in 1974. After completing a four-year post-doctoral fellowship in
Virology,  again at UCLA,  he spent four years as an assistant  professor at the
University  of Colorado  Health  Sciences  Center in Denver





before  accepting a position at  Immunological  Associates  of Denver  (IAD),  a
specialty reference testing laboratory.

Xtrana,  Inc.  develops,  manufactures and markets novel nucleic acid extraction
kits and detection  systems for use in molecular  diagnostics,  drug  discovery,
forensics,  research,  clinical and life sciences  markets.  To learn more about
Xtrana, visit the Company's web site at www.xtrana.com.

This Press Release contains forward-looking  statements (identified by the words
"estimate,"  "anticipate," "expect," "believe," and similar expressions),  which
are based upon management's  current  expectations and speak only as of the date
made. These forward-looking  statements are subject to risks,  uncertainties and
factors that could cause actual  results to differ  materially  from the results
anticipated in the forward-looking  statements and include,  but are not limited
to, competitors'  pricing strategies and technological  innovations,  changes in
health care and government  regulations,  litigation  claims,  foreign  currency
fluctuation,  product  acceptance,  as well as other  factors  discussed  in the
Company's last Report on Form 10-KSB.

- --------------------------------------------------------------------------------
Contact:
     Xtrana, Inc.
     Timothy Dahltorp, 303-466-4424